RxDoctor Payments Data

Lilliam Chiques-Colon, MD

Internal Medicine · Lakeland, FLNPI 1003922048

Payments from drug & device makers

$3,852in general payments, 2019–2025

Across 260 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$357
  • Novartis$317
  • AstraZeneca$196
  • Lilly USA, LLC$195
  • GSK$191
  • plus $922 from 13 others

What the payments were for

  • Food & beverage$3,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,852 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$420,910
Medicare patients
1,633
Services billed
6,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$175,740
EliquisApixaban131$130,156
MounjaroTirzepatide101$113,349
JardianceEmpagliflozin60$57,910
JanuviaSitagliptin Phosphate17$23,225
XareltoRivaroxaban14$22,035
TrulicityDulaglutide19$20,052
RybelsusSemaglutide12$16,910
ArexvyRsvpref3 Antigen/As01e/Pf52$15,850
Tresiba Flextouch U-100Insulin Degludec14$13,663
ShingrixVaricella-Zoster Ge/As01b/Pf43$9,551
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$8,263
Atorvastatin Calcium608$6,108
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$4,799
Rosuvastatin Calcium257$3,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,674$192,650160 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$195$135,655156 claims
PfizerEliquis$357$130,156131 claims
Boehringer IngelheimJardiance$101$57,91060 claims
GSKArexvy, Shingrix$191$25,40195 claims
MerckJanuvia$59$23,22517 claims
Johnson & JohnsonXarelto$127$22,03514 claims
AstraZenecaSymbicort$196$2,87312 claims
AbbVieSynthroid$138$2,72337 claims
Sanofi-aventis U.S. LLCLantus$42$1,61211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →